Polymorphisms in the CD6-ALCAM axis may modulate psoriasis risk and outcomes
- 5 April 2024
- journal article
- research article
- Published by Elsevier in Human Immunology
- Vol. 85 (3) , 110797
Abstract
No abstract availableKeywords
Funding Information
- Instytut Immunologii i Terapii Doświadczalnej, im. Ludwika Hirszfelda Polskiej Akademii Nauk (14/2018)
This publication has 45 references indexed in Scilit:
- Biologics for the primary care physician: Review and treatment of psoriasisDisease-a-Month, 2019
- Clinical and experimental evidence for targeting CD6 in immune-based disordersAutoimmunity Reviews, 2018
- The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onsetHuman Immunology, 2018
- Autoimmune aspects of psoriasis: Heritability and autoantigensAutoimmunity Reviews, 2017
- Recent Highlights in Psoriasis ResearchJournal of Investigative Dermatology, 2017
- ALCAM and CD6 — multiple sclerosis risk factorsJournal of Neuroimmunology, 2014
- ALCAM — Novel multiple sclerosis locus interfering with HLA-DRB1*1501Journal of Neuroimmunology, 2013
- PSORS2 Is Due to Mutations in CARD14The American Journal of Human Genetics, 2012
- Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in SpainJournal of Neuroimmunology, 2010
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008